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using Ingenix® data (2002-05). The analysis included elderly individuals aged ≥65 
years (47.9% females) on oral treatment for diabetes (insulin users excluded), 
classified as SU users (n=20,741) and non-users (n=22,114) at baseline. RESULTS: 
During the follow-up, we identified 420 cases of incident hip fractures in the SU 
group and 228 in non-SU group; unadjusted odds ratio (OR) for hip fracture risk 
was 1.98 (95% confidence intervals [CI]:1.69-2.33). In a multivariable logistic 
regression analysis simultaneously accounting for propensity to use SU and for 
potential confounders (age, gender, health insurance, geographic region, CVD, 
stroke, osteoporosis, dementia, hypertension, and use of steroids, 
benzodiazepines, anti-depression, anti-psychotic, anti-convulsant therapy and 
treatment for osteoporosis), the adjusted OR was 1.60 (95%CI: 1.35-1.90). This 
association was similar among men (210 cases; OR=1.68; 95%CI: 1.24-2.26) and 
women (438 cases; OR: 1.56; 95%: 1.27-1.92). In addition, SU users also had higher 
risk of hypoglycemia compared to non-users (5.8% vs. 2.1%). Furthermore, 
hypoglycemia was more common among hip fracture cases (12.0%) compared to 
non-cases (3.8%); the multivariable OR for hypoglycemia-fracture association 
adjusted for the above covariates was 1.81 (95% CI: 1.40-2.34). CONCLUSIONS: 
These results suggest that SU may be associated with increased risk of hip 
fracture in elderly men and women with diabetes, possibly related to elevated 
risk of hypoglycemia-induced falls. These findings need to be confirmed in 
future studies which should also further investigate the interrelationships of SU 
use with hypoglycemia, falls and fractures.  
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OBJECTIVES: Evaluate the external predictive power of the REVEAL HCV risk-
prediction model for HCC using data from the Veterans’ Administration [VA]. 
METHODS: The REVEAL investigators in Taiwan developed a risk-prediction 
model for HCC which has not been validated outside of Taiwan. The VA 
maintains a Clinical Case Registry [CCR] for approximately 360,000 patients with 
HCV infections which summarizes the utilization, diagnostic and lab value data 
for each patient going back to 1999. The patient’s initial HCV diagnosis date is set 
as the index date. VA patients were selected using the REVEAL 
inclusion/exclusion criteria and were then screened for baseline [+/- 6 months of 
index date] data on ALT, ALT/AST ratio, cirrhosis, HCV viral load and genotype. 
The area under ROC was used to evaluate the performance of the risk models. 
RESULTS: A totoal of 47,578 VA HCV patients met study inclusion criteria. The 
VA sample varied significantly from the REVEAL sample in terms of male gender 
and race. The frequency of a baseline viral load > 23,000 IU/mL was 91% in the 
VA sample versus 35% Taiwan sample. The overall incidence of HCC following a 
5-year washout period was 2.1% [n=1,000]. Average REVEAL HCV risk scored 13.2 
[SD=2.4] for non-HCC patients and 14.9 [SD=2.4] in patients with HCC [p<0.0001]. 
The incidence of HCC in VA patients increased monotonically across risk score 
quintiles: 0.48% for the lowest quintile to 4.3% for the highest quintile of risk 
scores. The area under the ROC was 0.6924 when the REVEAL HCV model was 
applied to VA patients. CONCLUSIONS: HCV risk prediction models help 
physicians to identify and motivate high risk patients to initiate treatment. The 
REVEAL risk prediction model is robust even when used for VA patients who 
differ significantly from the Taiwan sample from which the risk score model was 
estimated.  
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OBJECTIVES: To evaluate health care costs of patients with schizophrenia and 
specific comorbidities relative to patients without schizophrenia with the same 
comorbidities. METHODS: Medicaid insurance claims databases from five states 
(from 2001-2010) were analyzed. Adults with ≥2 claims for schizophrenia, ≥12 
months of continuous eligibility prior to the first diagnosis (index date), and ≥1 
claim for important comorbidities (substance abuse, obesity, diabetes, metabolic 
syndrome, hyperlipidemia, hypertension, coronary artery disease, congestive 
heart failure, HIV, hepatitis C, and COPD) during the 12 months prior to the index 
date (baseline period) were selected. Patients with schizophrenia were matched 
1:1 with non-schizophrenia control patients based on baseline characteristics 
(propensity scores) and comorbidities common in schizophrenia (exact matching 
factors). All-cause and comorbidity-related monthly health care costs were 
calculated and compared between cohorts using nonparametric re-resampling 
methods. No adjustment was made for multiplicity. RESULTS: A total of 24,652 
schizophrenia and 24,652 patients without schizophrenia were matched. The 
most common comorbidities were hypertension (48.8%), substance abuse (39.1%), 
and diabetes (28.4%). The patients with schizophrenia incurred greater all-cause 
monthly health care costs (cost difference [95% CI], $978 [933-1,024]) and 
comorbidity-related costs (cost difference [95% CI], $288 [269-307]). Schizophrenia 
was also associated with significantly higher comorbidity-related costs in each 
comorbidity subgroup (among the three most common comorbidities: 99% higher 
in hypertension, 293% in substance abuse, and 105% in diabetes). CONCLUSIONS: 
This study show that patients with schizophrenia and comorbidities common in 
patients with schizophrenia had higher all-cause and comorbidity-related health 
care costs compared with patients without schizophrenia with the same 
comorbidities.  
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OBJECTIVES: Estimate annual per-patient medical, drug, and work-loss costs of 
diabetic foot ulcer (DFU) using de-identified administrative claims data. 
METHODS: DFU patients and non-DFU diabetic patients (controls) were 
identified using two databases: ages 65+ from a 5% random sample of Medicare 
beneficiaries (Standard Analytical Files, 2007-2010; DFU N=29,681, controls N= 
201,757) and ages 18-64 from a privately-insured population (OptumInsight, 
2007-2011; DFU N=5,681, controls N=113,337). Patients were required to be 
continuously eligible during the 12 months before (baseline) and 12 months after 
(study period) the index date (ie, the date of the most recent DFU diagnosis 
following 12 months without DFU diagnoses (DFU group); or the date of a 
random medical claim (controls)). DFU patients were matched to controls using 
propensity scores to account for baseline differences in demographics, 
comorbidities, resource utilization, and costs. Medical costs during the study 
period were calculated for both Medicare and privately-insured patients. Because 
drug and work-loss (absenteeism or disability) data were not available for 
Medicare patients, these costs were estimated for the privately-insured sample 
only. Wilcoxon signed-rank tests were used to compare differences in study 
period costs. RESULTS: Data for 4,536 matched pairs of privately-insured  
and 27,878 matched pairs of Medicare patients were analyzed. Incremental 
medical costs for DFU patients were $11,296 for Medicare ($27,040 vs $15,743) and 
$15,329 for privately-insured ($25,931 vs $10,602) patients. Two-thirds (66%) of 
the cost differential among the privately-insured was attributable to excess 
inpatient costs. For Medicare, all places of services (eg, inpatient, 
outpatient/physician, emergency department) contributed approximately 
equally to the medical cost differential. Among the privately-insured, DFU 
patients had excess drug costs of $958 ($4,377 vs $3,420) and excess work-loss 
costs of $3,053 (absenteeism: +$1,490, disability: +$1,564). (Comparisons 
significant at p<0.0001.) CONCLUSIONS: These findings suggest that presence of 
DFU imposes substantial burden on payers beyond that of standard diabetes 
care.  
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OBJECTIVES: Previous research demonstrated that in some patients taking 
opioid analgesics for chronic pain there were significantly higher costs among 
those with concurrent exposures to CYP450-metabolized medications with the 
potential to cause a drug-drug interaction (pDDI), compared to matched patients 
without such exposures. The objectives of this study are to evaluate the 
prevalence of and health care costs associated with pDDIs that may cause major 
interactions in patients chronically taking long-acting opioid (LAO) analgesics. 
METHODS: Using the MarketScan® Commercial Database (2008-2010), cohorts 
were constructed of patients who were dispensed LAOs for >=30 days, both with 
and without pDDI exposures. Propensity score matching was used to mitigate 
the impact of selection bias. Costs were analyzed with a linear model for 
differences and a generalized linear model for ratios. RESULTS: Based on the 
final sample of 57,752 patients, the prevalence of major pDDIs was 5.7% in the 
90-day observation period. Oxycodone was the most common opioid among 
these pDDIs pairs, accounting for 57.3% of patients, followed by fentanyl (32.9%), 
methadone (18.3%) and codeine (1.8%). The most common precipitant drugs 
were fluconazole (34.5%), diltiazem (14.0%), clarithromycin (11.4%) and verapamil 
(10.9%). Based on the 99th percentile cost cutoff in the propensity score matched 
cohorts, the estimated mean monthly overall health care costs from the 
multivariate linear model were $3366 and $2757 for the pDDI-major cohort and 
no-pDDI cohort, respectively, a $609 difference. The generalized linear model 
provided similar results, with an estimated cost ratio of 1.232 (p-value < 0.01). 
The difference in monthly health care cost was mainly driven by outpatient 
medical cost ($257 difference, ratio 1.219, p- value <0.01) and inpatient medical 
cost ($289 difference, p-value = 0.11). CONCLUSIONS: Among patients chronically 
taking LAO analgesics, the exposure to major pDDIs is costly and worthy of 
efforts to avoid such exposures.  
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OBJECTIVES: Propensity score (PS) is widely used in observational study. It is 
usually estimated over entire study time period. However, pattern of medication 
use is changed over time. The PS which is estimated without taking into account 
time might be biased. Little is known about the effects of time on propensity 
score. This study aims to determine the differences of PS estimated by 
conventional PS and time-specific PS approaches and their effects on estimates 
of treatment effects. METHODS: A retrospective database analysis at a 
University-affiliated hospital in Thailand was used. Patients who aged 18 years 
